Iconic Minerals Ltd. announced new assay results from six drill holes at its New Pass gold property in Nevada, revealing significant near-surface gold and silver mineralization not included in historic resources. Five holes showed continuous mineralized intervals ranging from 30 to 180 feet, with gold grades around 0.35 g/t and silver grades reaching up to 42.7 g/t. The results support the potential for expanding the known resource, with further metallurgical testing and analysis planned. The property remains open for exploration along strike and at depth, indicating promising growth opportunities.
Iconic Minerals' recent assay results at New Pass gold property provide context for gold-related assets. For readers following Basic Materials-sector US stocks on Pluang, here is the market snapshot as of Sep 17, 2026 19:11 WIB: 27 of 31 stocks rose today. Among notable movers, Newmont Corporation (NEM) traded at USD 124.43 with a 1-day change of +2.19% and a typical hold time of 57 days, while Agnico Eagle Mines Ltd (AEM) reached USD 199.78 with a +2.15% change and 100% buy order activity. Barrick Gold Corp (B) was priced at USD 43.45, up +2.12%, with 87% sell order activity and a 54-day hold time.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
